Identification

Name
Paromomycin
Accession Number
DB01421
Type
Small Molecule
Groups
Approved, Investigational
Description

An oligosaccharide antibiotic produced by various streptomyces. [PubChem]

Structure
Thumb
Synonyms
  • (1R,2R,3S,4R,6S)-4,6-Diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside
  • Aminosidin
  • Aminosidine
  • Catenulin
  • Crestomycin
  • Estomycin
  • Hydroxymycin
  • Monomycin a
  • Neomycin e
  • Paromomicina
  • PAROMOMYCIN
  • Paromomycin i
  • Paromomycine
  • Paromomycinum
  • Paucimycin
  • Paucimycinum
  • Zygomycin a1
External IDs
ANTIBIOTIC 503-3 / ANTIBIOTIC SF 767B / R 400 / R-400
Product Ingredients
IngredientUNIICASInChI Key
Paromomycin sulfate845NU6GJPS1263-89-4LJRDOKAZOAKLDU-UDXJMMFXSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Humatin Cap 250mgCapsule250 mgOralErfa Canada 2012 Inc1994-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Paromomycin SulfateCapsule250 mg/1OralHeritage2009-10-22Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralSun Pharmaceutical Industries Limited1997-06-30Not applicableUs
Paromomycin SulfateCapsule250 mg/1OralDepartment Of State Health Services, Pharmacy Branch2009-10-22Not applicableUs
International/Other Brands
Humatin (Parke Davis (now Pfizer))
Categories
UNII
61JJC8N5ZK
CAS number
7542-37-2
Weight
Average: 615.6285
Monoisotopic: 615.296301173
Chemical Formula
C23H45N5O14
InChI Key
UOZODPSAJZTQNH-LSWIJEOBSA-N
InChI
InChI=1S/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
IUPAC Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(2R,3S,4R,5S)-5-{[(1R,2R,3S,5R,6S)-3,5-diamino-2-{[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-6-hydroxycyclohexyl]oxy}-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxy}oxane-3,4-diol
SMILES

Pharmacology

Indication

For the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.

Structured Indications
Pharmacodynamics

Paromomycin is a broad spectrum aminoglycoside antibiotic produced by Streptomyces rimosus var. paromomycinus. The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin.

Mechanism of action

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA. Bacterial proteins are synthesized by ribosomal RNA complexes which are composed of 2 subunits, a large subunit (50s) and small (30s) subunit, which forms a 70s ribosomal subunit. tRNA binds to the top of this ribosomal structure. Paramomycin binds to the A site, which causes defective polypeptide chains to be produced. Continuous production of defective proteins eventually leads to bacterial death.

TargetActionsOrganism
A30S ribosomal protein S10
inhibitor
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
Absorption

Poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Paromomycin Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AceclofenacAceclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AcemetacinAcemetacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Paromomycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Paromomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumParomomycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidParomomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Paromomycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Paromomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
AmpicillinThe serum concentration of Paromomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Paromomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumParomomycin may increase the respiratory depressant activities of Atracurium.Experimental
Atracurium besylateParomomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Bacampicillin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Paromomycin.Investigational
BendazacBendazac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Paromomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Botulinum Toxin Type AParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BParomomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Paromomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Paromomycin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
CarbenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of Paromomycin can be decreased when it is combined with Carbenicillin indanyl.Approved
CarboplatinParomomycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Paromomycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
CisatracuriumParomomycin may increase the respiratory depressant activities of Cisatracurium.Experimental
Cisatracurium besylateParomomycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Paromomycin.Approved
Clodronic AcidParomomycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateParomomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Paromomycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineParomomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Paromomycin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
DecamethoniumParomomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Paromomycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Paromomycin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Paromomycin.Approved
Domoic AcidParomomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideParomomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Paromomycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Paromomycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Etidronic acidParomomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Flucloxacillin.Approved
FlunixinFlunixin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Paromomycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Paromomycin.Approved, Vet Approved
GallamineParomomycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideParomomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Paromomycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
IbandronateParomomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Paromomycin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Paromomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MecamylamineParomomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
MetampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Paromomycin can be decreased when it is combined with Meticillin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Paromomycin.Experimental
MetocurineParomomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideParomomycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Paromomycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumParomomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Paromomycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinParomomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Paromomycin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Paromomycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Paromomycin.Approved
OxacillinThe serum concentration of Paromomycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
PamidronateParomomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumParomomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Paromomycin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Paromomycin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Paromomycin.Experimental
PhenoxymethylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Paromomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumParomomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Paromomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Paromomycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Paromomycin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Procaine benzylpenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
PropicillinThe serum concentration of Paromomycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Paromomycin.Experimental
PTC299PTC299 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
PyrantelParomomycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumParomomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental, Investigational
RisedronateParomomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumParomomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
SuccinylcholineParomomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Paromomycin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Paromomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Paromomycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Paromomycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Paromomycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateParomomycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateParomomycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Paromomycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Paromomycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidParomomycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Paromomycin.Approved
TranilastTranilast may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Paromomycin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational
TubocurarineParomomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Paromomycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Paromomycin.Approved
VecuroniumParomomycin may increase the respiratory depressant activities of Vecuronium.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidParomomycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Withdrawn
Food Interactions
  • Take with food.

References

Synthesis Reference

Federico Arcamone, Giuseppe Cassinelli, "Paromomycin derivatives and process for the preparation thereof." U.S. Patent US4021601, issued October, 1967.

US4021601
General References
  1. Vicens Q, Westhof E: Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure. 2001 Aug;9(8):647-58. [PubMed:11587639]
External Links
Human Metabolome Database
HMDB15490
KEGG Compound
C00832
PubChem Compound
165580
PubChem Substance
46505391
ChemSpider
145115
ChEBI
7934
ChEMBL
CHEMBL370143
Therapeutic Targets Database
DAP000407
PharmGKB
PA164784023
HET
PAR
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Paromomycin_sulfate
ATC Codes
A07AA06 — Paromomycin
AHFS Codes
  • 08:30.04
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
2CompletedTreatmentCryptosporidiosis infection / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentLeishmaniasis, Cutaneous4
2TerminatedTreatmentLeishmaniasis, Cutaneous2
3CompletedTreatmentLeishmaniasis, Cutaneous1
3CompletedTreatmentVisceral Leishmaniasis5
3Not Yet RecruitingTreatmentVisceral Leishmaniasis1
4CompletedTreatmentVisceral Leishmaniasis1
Not AvailableAvailableNot AvailableLeishmaniasis, Cutaneous1
Not AvailableCompletedTreatmentTuberculosis, Pulmonary1
Not AvailableCompletedTreatmentVisceral Leishmaniasis1
Not AvailableTerminatedTreatmentCryptosporidiosis infection / Human Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg
CapsuleOral250 mg/1
Prices
Unit descriptionCostUnit
Paromomycin 250 mg capsule5.67USD capsule
Humatin 250 mg capsule2.67USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility79.7 mg/mLALOGPS
logP-2.9ALOGPS
logP-8.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)12.23ChemAxon
pKa (Strongest Basic)9.94ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count19ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area347.32 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity134.24 m3·mol-1ChemAxon
Polarizability60.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 4,5-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C5-positions.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
4,5-disubstituted 2-deoxystreptamines
Alternative Parents
O-glycosyl compounds / Disaccharides / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Tetrahydrofurans / 1,2-aminoalcohols / Oxacyclic compounds / Acetals
show 4 more
Substituents
4,5-disubstituted 2-deoxystreptamine / Disaccharide / Glycosyl compound / O-glycosyl compound / Aminocyclitol or derivatives / Cyclohexanol / Cyclohexylamine / Cyclitol or derivatives / Oxane / Tetrahydrofuran
show 16 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
aminoglycoside antibiotic, amino cyclitol glycoside (CHEBI:7934)

Targets

Kind
Protein
Organism
Thermus thermophilus (strain HB8 / ATCC 27634 / DSM 579)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
Part of the top of the 30S subunit head.
Gene Name
rpsJ
Uniprot ID
Q5SHN7
Uniprot Name
30S ribosomal protein S10
Molecular Weight
11929.82 Da
References
  1. Dlugosz M, Trylska J: Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. doi: 10.1021/jp8112914. [PubMed:19438282]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Konno T, Kurita D, Takahashi T, Muto A, Himeno H: Initiation-shift of trans-translation by aminoglycosides. Nucleic Acids Symp Ser (Oxf). 2004;(48):299-300. [PubMed:17150597]
  4. Chao PW, Chow CS: Monitoring aminoglycoside-induced conformational changes in 16S rRNA through acrylamide quenching. Bioorg Med Chem. 2007 Jun 1;15(11):3825-31. Epub 2007 Mar 13. [PubMed:17399988]

Drug created on July 24, 2007 04:03 / Updated on October 02, 2017 04:58